- Home
- SLSR vs PHAR Comparison
SLSR vs PHAR Comparison
Compare SLSR & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLSR
- PHAR
- Stock Information
- Founded
- SLSR 2018
- PHAR 1988
- Country
- SLSR Canada
- PHAR Netherlands
- Employees
- SLSR N/A
- PHAR N/A
- Industry
- SLSR
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- SLSR
- PHAR Health Care
- Exchange
- SLSR NYSE
- PHAR Nasdaq
- Market Cap
- SLSR 539.0M
- PHAR 587.5M
- IPO Year
- SLSR N/A
- PHAR N/A
- Fundamental
- Price
- SLSR $3.18
- PHAR $8.62
- Analyst Decision
- SLSR Buy
- PHAR Strong Buy
- Analyst Count
- SLSR 2
- PHAR 3
- Target Price
- SLSR $10.00
- PHAR $30.00
- AVG Volume (30 Days)
- SLSR 47.8K
- PHAR 6.7K
- Earning Date
- SLSR 05-08-2025
- PHAR 03-13-2025
- Dividend Yield
- SLSR N/A
- PHAR N/A
- EPS Growth
- SLSR N/A
- PHAR N/A
- EPS
- SLSR N/A
- PHAR N/A
- Revenue
- SLSR N/A
- PHAR $297,200,000.00
- Revenue This Year
- SLSR N/A
- PHAR $8.26
- Revenue Next Year
- SLSR N/A
- PHAR $9.73
- P/E Ratio
- SLSR N/A
- PHAR N/A
- Revenue Growth
- SLSR N/A
- PHAR 21.15
- 52 Week Low
- SLSR $2.88
- PHAR $6.65
- 52 Week High
- SLSR $3.76
- PHAR $11.30
- Technical
- Relative Strength Index (RSI)
- SLSR 37.73
- PHAR 48.81
- Support Level
- SLSR $3.43
- PHAR $8.03
- Resistance Level
- SLSR $3.62
- PHAR $8.85
- Average True Range (ATR)
- SLSR 0.17
- PHAR 0.34
- MACD
- SLSR -0.02
- PHAR -0.01
- Stochastic Oscillator
- SLSR 6.45
- PHAR 51.73
About SLSR SOLARIS RESOURCES INC
Solaris Resources Inc is advancing a portfolio of copper and gold assets in the Americas, which includes a high-grade resource with expansion and additional discovery potential at the Warintza copper and gold project in Ecuador; discovery potential on the grass-roots Tamarugo project in Chile and Capricho and Paco Orco projects in Peru, and the La Verde joint venture project.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.